A new electronic device for subcutaneous injection of IFN-β-1a

Expert Review of Medical Devices

Volumn 8, Issue 5, 2011, Pages 543-553

  Exell, Simon ^a   Verdun, Elisabetta ^a   Driebergen, Reinoud ^a  

^a MERCK SERONO S A   (Switzerland)

Author keywords

adherence; disease modifying drug; electronic injection device; IFN 1a; multiple sclerosis; RebiSmart

Indexed keywords

ADHERENCE; DISEASE-MODIFYING DRUG; ELECTRONIC DEVICE; ELECTRONIC INJECTION; HEALTH CARE PROVIDERS; MULTIPLE SCLEROSIS;

DISEASES; PATIENT TREATMENT; THERMOELECTRIC EQUIPMENT;

ELECTRON DEVICES;

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ARTICLE; AUTOMATION; COST; DEVICE; DRUG DELIVERY SYSTEM; ELECTRONICS; HUMAN; MULTIPLE SCLEROSIS; NEEDLE; PATIENT COMPLIANCE; RELAPSE; SELF INJECTION; SYRINGE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; EQUIPMENT AND SUPPLIES; EQUIPMENT DESIGN; HUMANS; INJECTIONS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MEDICATION ADHERENCE; MIDDLE AGED; MULTIPLE SCLEROSIS; SELF CARE;

EID: 80052279149     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.11.29     Document Type: Article

References (31)

1. Inglese M. Multiple sclerosis: New insights and trends. AJNR Am. J. Neuroradiol. 27, 954-957 (2006).
2. Frohman EM, Stuve O, Havrdova E et al. Therapeutic considerations for disease progression in multiple sclerosis: Evidence, experience, and future expectations. Arch. Neurol. 62(10), 1519-1530 (2005).
3. Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58(2), 169-178 (2002).
4. Tintoré M. Early MS treatment. Int. MS J. 14(3), 75 (2007).
5. Trojano M, Pellegrini F, Paolicelli D et al. Real-life impact of early interferon b therapy in relapsing multiple sclerosis. Ann. Neurol. 66(4), 513-520 (2009).
6. Al-Sabbagh A, Bennett R, Kozma C, Dickson M, Meletiche DM. Medication gaps in disease-modifying drug therapy for multiple sclerosis are associated with an increased risk of relapse: Findings from a national managed care database. J. Neurol. 255(Suppl. 2), S79 (2008). Claims database analysis showing that gaps in disease-modifying drug (DMD) therapy are associated with an increased risk of relapse.
7. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J. Manag. Care Pharm. 15(7), 543-555 (2009).
8. Brown BA. Natalizumab in the treatment of multiple sclerosis. Ther. Clin. Risk Manag. 5(3), 585-594 (2009).
9. Verdun E, Snow T, Russell S. Understanding and meeting the injection device needs of patients with multiple sclerosis: Results from an online survey. Patient Pref. Adherence (2011) (In press). . Online survey of patients' attitudes to injection devices, including RebiSmart™.
10. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J. Med. 10(9), 225 (2008).
11. Treadaway K, Cutter G, Salter A et al. Factors that influence adherence with disease-modifying therapy in MS. J. Neurol. 256(4), 568-576 (2009). Observational study using online questionnaires to assess factors that influence adherence to DMD therapy.
12. Chen CC, Kasven N, Karpatkin HI, Sylvester A. Hand strength and perceived manual ability among patients with multiple sclerosis. Arch. Phys. Med. Rehabil. 88(6), 794-797 (2007).
13. Patti F. Optimizing the benefit of multiple sclerosis therapy: The importance of treatment adherence. Patient Prefer. Adherence 4, 1-9 (2010).
14. Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J. Neurol. 255(Suppl. 6), 87-92 (2008).
15. Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med. 353(5), 487-497 (2005).
16. Devonshire V, Lapierre Y, Macdonell R et al. The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur. J. Neurol. 18(1), 69-77 (2011). Large observational study assessing factors that influence adherence to DMD therapy.
17. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: A non-experimental, retrospective, cohort study. Clin. Drug Investig. 30(2), 89-100 (2010). Claims database analysis showing that adherent patients tend to have a lower risk of relapses than nonadherent patients.
18. Jaber A, Bozzato GB, Vedrine L, Prais WA, Berube J, Laurent PE. A novel needle for subcutaneous injection of interferon b-1a: Effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurol. 8, 38 (2008).
19. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: Can delivery technology enhance patient motivation? Expert Opin. Drug Deliv. 6(9), 995-1002 (2009).
20. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon b-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult. Scler. 11(5), 585-591 (2005).
21. Brochet B, Lemaire G, Beddiaf A; l'Epicure Study Group. [Reduction of infection site reactions in multiple sclerosis (MS) patients newly started on interferon b 1b therapy with two different devises]. Rev. Neurol. (Paris) 162(6-7), 735-740 (2006).
22. Cramer JA, Cuffel BJ, Divan V, Al-Sabbagh A, Glassman M. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol. Scand. 113(3), 156-162 (2006).
23. Bayas A, Japp G, Fulda U, Kallmann BA. [Injection devices in the basic therapy of multiple sclerosis. Survey among neurologists, MS nurses and patients]. Nervenheilkunde 29, 57-62 (2010).
24. Dahlgren J. Easypod: A new electronic injection device for growth hormone. Expert Rev. Med. Devices 5(3), 297-304 (2008).
25. Giovannoni G, Barbarash O, Casset-Semanaz F et al. Safety and immunogenicity of a new formulation of interferon b-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult. Scler. 15(2), 219-228 (2009).
26. McKeage K, Wagstaff AJ. Subcutaneous interferon-b-1a: New formulation. CNS Drugs 21(10), 871-876 (2007).
27. Devonshire V, Arbizu T, Borre B et al. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon b-1a in relapsing multiple sclerosis: An international, single-arm, multicentre, Phase IIIb study. BMC Neurol. 10(1), 28 (2010). . International, 12-week, Phase IIIb study assessing patient-rated suitability of RebiSmart™.
28. Devonshire V, Feinstein A, Moriarty P. MEASURE: A Multicentre, single-arm observational, 96-week, Phase IV study to Evaluate treatment Adherence when using RebiSmart™ for Self-injection of Rebif® in mUlti-dose cartridges in subjects with Relapsing multiplE sclerosis. J. Neurol. Sci. 285, S203 (2009).
29. Baldinetti F, Ghazi-Visser L. Assessment of adherence to subcutaneous interferon b-1a treatment in daily practice among patients with relapsing multiple sclerosis using an electronic self-injection device. J. Neurol. 257(Suppl. 1), S191 (2010).
30. Singer B, Wray S, Miller T et al. Electronic autoinjector for self-injected subcutaneous interferon b-1a. Int. J. MS Care. 12(Suppl. 1), 89 (2010).
31. Girouard N, Theoret G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. Can. J. Neurosci. Nurs. 30, 18-25 (2008).